Study #2020-0616
Phase I Study of Tegavivint (BC-2059) in Patients with Relapsed and Refractory Leukemias
MD Anderson Study Status
Not Accepting
Treatment Agent
Decitabine, Tegavivint
Description
This phase I trial is to find out the best dose and side effects of tegavivint in treating patients with leukemia that has come back (relapsed) or does not response to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint in combination with decitabine may help control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Leukemia, Refractory Leukemia
Study phase:
Phase I
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.